European Medicines Agency Confirms Positive Benefit-Risk Balance For Rosiglitazone And Pioglitazone

Finalising a review of the benefits and risks of the thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos), the European Medicines Agency has concluded that the benefits of these antidiabetic medicines continue to outweigh their risks in the approved indications. However, the Agency recommended changing the product information for rosiglitazone and agreed further initiatives to increase scientific knowledge on the safety of both medicines. [click link for full article]

More: continued here

Filed under: Diabetes on October 20th, 2007